At Uromigos Live 2024, a panel moderated by Tom Powles focused on IO rechallenge in renal cell carcinoma, featuring discussion on new trial data, The panel included Brian Rini, along with Tian Zhang, MD, UT Southwestern Medical Center; Toni Choueiri, MD, Dana-Farber Cancer Center; and David McDermott, MD, Beth Israel Deaconess Medical Center.
In part three of this session, the panel discusses the use of immunotherapy, specifically PD-1 based therapies, in renal cell carcinoma and the evolving practices regarding re-challenging patients with these therapies. The panel explores the effectiveness of reintroducing PD-1 inhibitors in patients who relapse after adjuvant pembrolizumab, focusing on the timing of relapse and how it impacts the decision to retry immunotherapy. The discussion touches on the challenges of defining primary resistance, treatment intervals, and the importance of novel combination approaches.
Uromigos Live 2024 RCC IO Rechallenge Part 3: IO Therapy After Adjuvant Pembrolizumab?
By Thomas Powles, MBBS, MRCP, MD, Brian Rini, MD, FASCO, Tian Zhang, MD, Toni Choueiri, MD, David F. McDermott, MD - Last Updated: October 30, 2024Related Posts
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
The panel concludes with future directions in RCC, including HIF inhibitors and biomarker-guided adjuvant strategies.
The panel considers how managing real-world patients on novel therapies like belzutifan presents a multitude of challenges.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.